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Towards a trial-based deﬁ nition of vitamin D deﬁ ciency
Vitamin D is not a vitamin (ie, an essential micronutrient), 
but rather the parent compound of an endocrine system 
primarily involved in the regulation of intestinal calcium 
absorption. It is synthesised in the skin as a result of the 
action of ultraviolet (UV) light on 7-dehydrocholesterol, 
and oral intake (other than supplement use) makes 
a negligible contribution to vitamin D concentration 
in most people. It is not biologically active, but two 
metabolites, 25-hydroxyvitamin D (25[OH]D) and 
1,25-dihydroxyvitamin D, bind to the vitamin D receptor 
(the latter with a 1000 times the aﬃ  nity of the former) 
and stimulate the active absorption of calcium in the 
upper small bowel. Both metabolites circulate bound to 
vitamin D binding protein. 
Severe vitamin D deﬁ ciency results in hypocalcaemia 
and hypophosphataemia, resulting in under-
mineralisation of bone (osteomalacia). Before skeletal 
maturity, this deﬁ ciency presents as rickets. Circulating 
concentrations of 25(OH)D are aﬀ ected by sunlight 
exposure, and are reduced in people who are seldom 
outdoors (eg, those who are frail), women who are 
permanently veiled, and in people with dark skin 
(in whom melanin absorbs the UV light). Obesity 
also reduces 25(OH)D, since fat-soluble vitamin D is 
sequestered into adipose tissue, as do inﬂ ammatory 
states (a poorly understood phenomenon that is partly 
due to changes in vitamin D binding protein).1 
Circulating concentrations of 25(OH)D are reduced 
in almost every medical or psychiatric disorder in 
which they have been studied,2 and have a U-shaped 
association with mortality.3 In pregnancy, low maternal 
25(OH)D concentrations have been associated with 
gestational diabetes, pre-eclampsia, infants who are 
small for their gestational age, and lower oﬀ spring bone 
mass.4 From these associations has arisen the widespread 
belief that vitamin D deﬁ ciency is involved in the 
causation of a wide range of pathological abnormalities, 
resulting in advocacy for widespread supplementation.
After a decade of publications demonstrating vitamin 
D’s many disease associations, we are now entering a 
new era in which trials of vitamin D supplementation 
are being completed. These oﬀ er the possibility of 
determining which associations represent causation, 
and of guiding clinical practice. The MAVIDOS study, 
presented in The Lancet Diabetes & Endocrinology by 
Cyrus Cooper and colleagues,5 shows that cholecalciferol 
1000 IU/day does not aﬀ ect neonatal bone mineral 
content (BMC) when given to pregnant women with 
baseline 25(OH)D concentrations between 25 nmol/L 
and 100 nmol/L. In a prespeciﬁ ed subgroup analysis, 
an interaction was noted between the eﬀ ects of 
treatment allocation and season of birth on oﬀ spring 
BMC (pinteraction=0·04): for births occurring in winter, 
vitamin D supplementation increased neonatal BMC 
by almost 10% (p=0·004), and fat mass was increased 
by 17% (p=0·008). Increases in neonatal bodyweight 
after maternal vitamin D supplementation have been 
suggested in previous similar trials,6 and the higher fat 
mass observed in the supplemented group in Cooper and 
colleagues’ study might be mechanistically related to the 
bone changes, since fat mass is a dynamic determinant 
of bone mass in adult life.7 The subgroup of women who 
gave birth in winter had a mean 25(OH)D concentration 
of 30 nmol/L (SD 16) at 34 weeks’ gestation, compared 
with concentrations of 50–60 nmol/L in the summer and 
autumn birth subgroups, suggesting a threshold at which 
supplements might be of value.
To the purist, MAVIDOS shows no beneﬁ t from 
vitamin D supplementation in pregnancy. However, 
the subgroup analysis provides data that might 
help to address the vexed issue of what constitutes 
vitamin D deﬁ ciency. The ﬁ ndings suggest that when 
25(OH)D concentration is lower than 30 nmol/L, 
neonatal fat and bone mass could be aﬀ ected by 
maternal supplementation. This threshold is very similar 
to that for which beneﬁ cial eﬀ ects on adult bone density 
and for prevention of osteomalacia have been reported.8 
Similar post-hoc trial evidence has suggested that when 
25(OH)D concentration is lower than 25–30 nmol/L, 
supplementation might reduce exacerbations of chronic 
obstructive pulmonary disease,9 and reduce mortality 
in people who are critically ill.10 By contrast, Bolland and 
colleagues11,12 have produced persuasive evidence that 
supplements given to cohorts with higher 25(OH)D 
concentrations (generally >30 nmol/L), do not aﬀ ect falls, 
fractures, myocardial infarction, stroke, or cancer. 
Together, these ﬁ ndings suggest that vitamin D 
might be causally associated with some disorders when 
25(OH)D concentration is lower than 25–30 nmol/L. The 
manifold disease associations with higher concentrations 
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Alirocumab and evolocumab, both fully human 
monoclonal antibodies that bind to plasma proprotein 
convertase subtilisin/kexin type 9 (PCSK9), were recently 
approved for the treatment of hypercholesterolaemia 
in Europe and the USA. PCSK9 is mainly synthesised by 
the liver and binds to LDL receptors, thereby precluding 
their recycling to the hepatocyte surface, reducing 
LDL clearance from plasma, and thus increasing the 
concentration of LDL cholesterol.1 
Type 2 diabetes is associated with an increased lifetime 
risk of cardiovascular disease, and practice guidelines 
recommend intensive LDL cholesterol-lowering treat-
ment to prevent major atherosclerotic events.4 Patients 
with type 2 diabetes have therefore become a natural 
population in which to test PCSK9 inhibitors.
In The Lancet Diabetes & Endocrinology, Naveed Sattar 
and colleagues5 present the results of a meta-analysis 
of three 12-week phase 3 trials that compared 
of serum 25(OH)D probably reﬂ ect the eﬀ ects of obesity 
and inﬂ ammatory states, and the fact that individuals 
who are unwell from any cause spend less time outdoors. 
Thus, the progressive upward drift in reference ranges 
for 25(OH)D over the past two decades, which has been 
based on its disease associations, is inappropriate, and the 
lower bound of this range should reﬂ ect the results from 
clinical trials of vitamin D supplementation. Future trials 
of vitamin D supplements should recruit participants with 
25(OH)D concentrations of lower than 25–30 nmol/L, 
since there is little evidence of beneﬁ t when baseline 
25(OH)D is above this concentration, in pregnancy or 
other contexts. If we are to embark on such trials, however, 
their ethics and cost–beneﬁ t require careful consideration, 
since we know that these concentrations of 25(OH)
D are associated with osteomalacia and that calciferol 
400 U/day (or an equivalent dose at longer inter vals) can 
correct this deﬁ ciency safely and at minimal cost. When 
the 25–30 nmol/L threshold is used, vitamin D deﬁ ciency 
becomes a much less prevalent condition that, in most 
clinical contexts, can be reliably predicted from clinical risk 
factors alone.13 Therefore, in pregnancy and other contexts, 
we should be moving to targeted supplementation with 
vitamin D in individuals likely to have concentrations 
of lower than 25–30 nmol/L, and away from mass 
medication, which is without proved beneﬁ t.
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PCSK9 inhibition in type 2 diabetes: so far so good, but not 
there yet
